MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts
NEW YORK, May 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts
Summary
This report focuses on the Diagnostic Cardiac Biomarkers market in South America, principally Brazil. The ACS in vitro diagnostics market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, the emergence of pipeline biomarker tests will change the landscape of ACS in vitro diagnostic testing and is expected to provide enhancements in the early diagnosis of the disease. Also, due to the increasing number of cases of ACS in Brazil, GlobalData expects this market to also be of key interest to stakeholders.
Acute coronary syndrome (ACS) consists of two major diseases, myocardial infarction (MI) and unstable angina, with the former being one of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency rooms every year with symptoms such as chest pain, and these patients are typically assessed with in vitro diagnostic cardiac biomarker tests. The ACS diagnostic cardiac biomarker reagents market is dominated by the cardiac troponins, the gold-standard biomarkers for the diagnosis of MI.
Scope
- An overview of ACS, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized Brazil ACS in vitro diagnostic testing reagents market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
- Investigation of current and future market competition for diagnostic cardiac biomarkers for ACS
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the diagnostic cardiac biomarkers for ACS sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists
Reasons to buy
- Understand the trends shaping and driving Brazil diagnostic cardiac biomarkers for ACS.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in Brazil diagnostic cardiac biomarkers for ACS Market through 2018.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in Brazil diagnostic cardiac biomarkers for ACS market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 12
1.2 List of Figures 14
2 Introduction 15
2.1 Catalyst 15
3 Disease Overview 16
3.1 Acute Coronary Syndromes 16
3.2 Anatomy and Physiology 17
3.3 Pathophysiology 18
3.4 Clinical Presentation 19
3.4.1 Symptoms 19
3.4.2 Diagnosis 19
3.5 Clinical Outcomes 24
3.5.1 Treatment Options 24
3.5.2 Treatment Paradigm 28
3.6 Epidemiology 29
3.7 Economic Impact 30
4 Competitive Assessment 31
4.1 Overview 31
4.2 Cardiac Troponins 32
4.2.1 Overview 32
4.2.2 Clinical Application and Utility 33
4.2.3 Market Penetration 37
4.2.4 SWOT Analysis 37
4.3 Creatine Kinase-MB 38
4.3.1 Overview 38
4.3.2 Clinical Application and Utility 39
4.3.3 Market Penetration 40
4.3.4 SWOT Analysis 40
4.4 Myoglobin 41
4.4.1 Overview 41
4.4.2 Clinical Application and Utility 42
4.4.3 Market Penetration 43
4.4.4 SWOT Analysis 43
4.5 Point-of-Care 44
4.5.1 Overview 44
4.5.2 Clinical Application and Utility 45
4.5.3 Market Penetration 48
4.5.4 SWOT Analysis 49
5 Unmet Needs 50
5.1 Overview 50
5.2 Earlier Diagnosis 51
5.3 Specificity and False Positives 53
5.4 Interpretation of Biochemical Assay Results 54
5.5 Markers for Myocardial Ischemia 56
5.6 Troponin Assay Sensitivity 57
6 Pipeline Products 58
6.1 Overview 58
6.2 BAG3 (Biouniversia) 59
6.2.1 Overview 59
6.2.2 SWOT Analysis 59
6.3 CAVARISK (Cavadis) 59
6.3.1 Overview 59
6.3.2 SWOT Analysis 59
6.4 CardioScore (BG Medicine) 60
6.4.1 Overview 60
6.4.2 SWOT Analysis 60
6.5 Circulating Endothelial Cells 61
6.5.1 Overview 61
6.5.2 SWOT Analysis 62
6.6 Copeptin (Thermo Scientific) 62
6.6.1 Overview 62
6.6.2 SWOT Analysis 65
6.7 Heart-Type Fatty Acid Binding Protein 65
6.7.1 Overview 65
6.7.2 SWOT Analysis 67
6.8 MIRISK VP Assessment (Aviir) 68
6.8.1 Overview 68
6.8.2 SWOT Analysis 68
6.9 Early Emerging Tests 69
6.9.1 Heart Diagnostic Assay (Prevencio/University of Pittsburgh) 69
6.9.2 Sentinel CVD (GeneNews) 69
6.9.3 SomaScan Cardiovascular Assay (SomaLogic) 69
7 Industry Overview 70
7.1 ACS Diagnostic Biomarker Testing Trends 70
7.2 Market Access 71
7.3 Reimbursement Trends 72
7.4 Regulatory Environment 73
7.4.1 Product Recalls 73
8 Current and Future Players 75
8.1 Overview 75
8.2 Trends in Corporate Strategy 75
8.3 Abbott Diagnostics 76
8.3.1 Overview 76
8.3.2 Portfolio Assessment 76
8.4 Alere 78
8.4.1 Overview 78
8.4.2 Portfolio Assessment 79
8.5 Beckman Coulter 80
8.5.1 Overview 80
8.5.2 Portfolio Assessment 81
8.6 bioMérieux 82
8.6.1 Overview 82
8.6.2 Portfolio Assessment 83
8.7 Mitsubishi Chemical Medience Corporation 84
8.7.1 Overview 84
8.7.2 Portfolio Assessment 85
8.8 Ortho-Clinical Diagnostics 86
8.8.1 Overview 86
8.8.2 Portfolio Assessment 87
8.9 Radiometer Medical 88
8.9.1 Overview 88
8.9.2 Portfolio Assessment 89
8.10 Randox Laboratories 90
8.10.1 Overview 90
8.10.2 Portfolio Assessment 91
8.11 Response Biomedical 92
8.11.1 Overview 92
8.11.2 Portfolio Assessment 93
8.12 Roche Diagnostics 94
8.12.1 Overview 94
8.12.2 Portfolio Assessment 95
8.13 Siemens Healthcare 96
8.13.1 Overview 96
8.13.2 Portfolio Assessment 97
8.14 Thermo Scientific 98
8.14.1 Overview 98
8.14.2 Portfolio Assessment 99
9 Market Drivers and Opportunities and Barriers 100
9.1 Market Drivers 100
9.1.1 Uptake of Pipeline Biomarker Tests 100
9.1.2 Increasing Adoption of POC Testing 101
9.1.3 Increasing Volume of Tests in the Emerging Market of Brazil 101
9.2 Market Opportunities 102
9.2.1 High-Sensitivity Troponin Assays 102
9.2.2 Enhancement in Sensitivity of Troponin POC Assays 104
9.2.3 New Pipeline Tests for Early Diagnosis of ACS 104
9.2.4 Emerging Markets 105
9.3 Market Barriers 106
9.3.1 Removal of CK-MB and Myoglobin from Testing Panels 106
9.3.2 Reimbursement 106
10 Country Outlooks and Forecasts 107
10.1 Market Overview 107
10.2 Brazil 107
11 Appendix 111
11.1 Bibliography 111
11.2 Abbreviations 123
11.3 Research Methodology 125
11.3.1 Overview 125
11.3.2 Coverage 125
11.3.3 Secondary Research 125
11.3.4 Forecast Methodology 126
11.4 Primary Research 127
11.5 Physicians and Specialists Included in this Study 128
11.6 About the Authors 129
11.6.1 Analysts 129
11.6.2 Global Head of Healthcare 130
11.7 About MediPoint 130
11.8 About GlobalData 130
11.9 Contact Us 131
11.10 Disclaimer 131
List of Tables
Table 1: Risk Factors Associated with ACS 21
Table 2: Properties of Common ACS and MI Diagnostic Biomarkers 23
Table 3: Diagnosis and Risk Stratification of ACS 24
Table 4: Common PCI Periprocedural Antithrombotic Drugs 25
Table 5: Common Drugs for Fibrinolysis 25
Table 6: Common Drugs for the Treatment of NSTEMI and UA 27
Table 7: Description of Direct and Indirect Economic Costs 30
Table 8: Product Profile – Cardiac Troponins 33
Table 9: Cardiac Troponin Concentrations of Selected Current Troponin Assays 34
Table 10: Cardiac Troponin Concentrations of Selected High-Sensitivity Troponin Assays 35
Table 11: Cardiac Troponins SWOT Analysis 37
Table 12: Product Profile – Creatine Kinase-MB 38
Table 13: Creatine Kinase-MB SWOT Analysis 40
Table 14: Product Profile – Myoglobin 41
Table 15: Myoglobin SWOT Analysis 43
Table 16: Product Profile – Point-of-Care Testing 44
Table 17: Cardiac Troponin Concentrations of POC Troponin Assays 46
Table 18: Point-of-Care Cardiac Panel SWOT Analysis 49
Table 19: ACS Cardiac Biomarker Product Pipeline 58
Table 20: BAG3 SWOT Analysis 59
Table 21: CAVARISK SWOT Analysis 59
Table 22: CardioScore SWOT Analysis 60
Table 23: Circulating Endothelial Cells SWOT Analysis 62
Table 24: Copeptin SWOT Analysis 65
Table 25: Heart-Type Fatty Acid Binding Protein SWOT Analysis 67
Table 26: MIRISK VP SWOT Analysis 68
Table 27: Company Profile – Abbott Diagnostics 76
Table 28: Abbott Diagnostics SWOT Analysis, 2013 77
Table 29: Company Profile – Alere 78
Table 30: Alere SWOT Analysis, 2013 79
Table 31: Company Profile – Beckman Coulter 80
Table 32: Beckman Coulter SWOT Analysis, 2013 81
Table 33: Company Profile – bioMérieux 82
Table 34: bioMérieux SWOT Analysis, 2013 83
Table 35: Company Profile – Mitsubishi Chemical Medience Corporation 84
Table 36: Mitsubishi Chemical Medience Corporation SWOT Analysis, 2013 85
Table 37: Company Profile – Ortho-Clinical Diagnostics 86
Table 38: Ortho-Clinical Diagnostics SWOT Analysis, 2013 87
Table 39: Company Profile – Radiometer Medical 88
Table 40: Radiometer Medical SWOT Analysis, 2013 89
Table 41: Company Profile – Randox Laboratories 90
Table 42: Randox Laboratories SWOT Analysis, 2013 91
Table 43: Company Profile – Response Biomedical 92
Table 44: Response Biomedical SWOT Analysis, 2013 93
Table 45: Company Profile – Roche Diagnostics 94
Table 46: Roche Diagnostics SWOT Analysis, 2013 96
Table 47: Company Profile – Siemens Healthcare 97
Table 48: Siemens Healthcare SWOT Analysis, 2013 97
Table 49: Company Profile – Thermo Scientific 98
Table 50: Thermo Scientific SWOT Analysis, 2013 99
Table 51: Major Events Affecting the ACS In Vitro Diagnostics Market 107
Table 52: Sales Forecasts for ACS In Vitro Diagnostic Testing Reagents in Brazil, ($m), 2009–2018 108
List of Figures
Figure 1: Anatomy of the Human Heart 17
Figure 2: Heart Muscle Damage, Atherosclerosis and Thrombosis 19
Figure 3: Strategy for Evaluating ACS 20
Figure 4: Treatment and Management of ACS 28
Figure 5: Annual Number of ACS Cases in South America (Brazil), 2009-2018 29
Figure 6: South America (Brazil) Market Share by Test Type for ACS In Vitro Diagnostic Testing Reagents, 2012 31
Figure 7: Estimated Brazil ACS Diagnostic Biomarker Testing Volumes, 2009 to 2018 70
Figure 8: Brazil Sales Forecast for ACS In Vitro Diagnostic Testing Reagents, ($m), 2009–2018 108
Figure 9: Brazil Market Share by Test Type for ACS In Vitro Diagnostic Testing Reagents, 2012 and 2018 110
Companies mentioned
Abbott Diagnostics
Alere
Beckman Coulter
bioMérieux
Mitsubishi Chemical Medience Corporation
Ortho-Clinical Diagnostics
Radiometer Medical
Randox Laboratories
Response Biomedical
Roche Diagnostics
Siemens Healthcare
Thermo Scientific
To order this report:
In_Vitro_Diagnostic Industry: MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article